Form 4: Corcept Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
Summary
- Grant/award: acquired 164 Common Stock at $113.38 ($18,594) on September 1, 2026; holds 13,590 after (Direct).
- Grant/award: acquired 164 Common Stock on September 1, 2026; holds 13,754 after (Direct).
- Tax/exercise-price withholding: disposed of 91 Common Stock at $113.38 ($10,318) on September 2, 2026; holds 13,663 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Gary Charles Robb — Officer (Chief Business Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Grant/award | Common Stock | 164 | $113 | $18.6K | 13,590 |
| 2026-09-01 | Grant/award | Common Stock | 164 | — | — | 13,754 |
| 2026-09-02 | Tax/exercise-price withholding | Common Stock | 91 | $113 | $10.3K | 13,663 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Grant/award (164 shares) |
| 2026-09-01 | Grant/award (164 shares) |
| 2026-09-02 | Tax/exercise-price withholding (91 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, neutral, Gary Charles Robb
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.